ISPOR Workshop: HEOR as a Compass, Not a Roadblock: How and When Development-Stage Biotech Companies Should Leverage HEOR

Neal Masia, PhD, Co-Founder and CEO of EntityRisk, will speak at this ISPOR Workshop. He will discuss when development-stage biotechs should implement HEOR capabilities and how these teams can maximize an organization’s clinical and commercial impact.

Upcoming: Let's meet in Philadelphia!

Join EntityRisk and industry leaders for a discussion on how HEOR and Market Access professionals are navigating the evolving policy, access, and value landscapes.

Come visit us at Booth #805.

About EntityRisk

EntityRisk integrates globally renowned health economics and policy expertise with PROVEN™, our advanced modelling software, to predict health outcomes, identify maximum value-based pricing, and substantiate evidence-generation investments.

10 of the Top 20 Biopharma Companies work with EntityRisk to navigate the shifting policy landscape and confidently choose and defend justifiable prices, inform evidence investments, and communicate and win on value.

10 / 20

Top Biopharma Companies

1,300+

Quality Checks

5

ML Modules

Leverage software built by a team with world- class scientific, engineering and industry credentials.